Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease

C Borghi, E Agabiti-Rosei, RJ Johnson… - European journal of …, 2020 - Elsevier
During the last century, there has been an increasing prevalence of hyperuricaemia noted in
many populations. While uric acid is usually discussed in the context of gout …

The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors

N Liu, H Xu, Q Sun, X Yu, W Chen… - Oxidative Medicine …, 2021 - Wiley Online Library
Uric acid is the end product of purine metabolism in humans. Hyperuricemia is a metabolic
disease caused by the increased formation or reduced excretion of serum uric acid (SUA) …

Uric acid and cardiovascular disease

G Ndrepepa - Clinica chimica acta, 2018 - Elsevier
Uric acid (UA) is an end product of purine metabolism in humans and great apes. UA acts as
an antioxidant and it accounts for 50% of the total antioxidant capacity of biological fluids in …

[HTML][HTML] Physiology of hyperuricemia and urate-lowering treatments

CL Benn, P Dua, R Gurrell, P Loudon, A Pike… - Frontiers in …, 2018 - frontiersin.org
Gout is the most common form of inflammatory arthritis and is a multifactorial disease
typically characterized by hyperuricemia and monosodium urate crystal deposition …

Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk

C Borghi, D Agnoletti, AFG Cicero, E Lurbe… - Hypertension, 2022 - Am Heart Assoc
Uric acid is the final product of purine metabolism, and its increased serum levels have been
directly involved in the pathogenesis and natural history of hypertension. The relationship …

Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (uric acid right for heart health) project

A Maloberti, C Giannattasio, M Bombelli… - High Blood Pressure & …, 2020 - Springer
Abstract The latest European Guidelines of Arterial Hypertension have officially introduced
uric acid evaluation among the cardiovascular risk factors that should be evaluated in order …

[HTML][HTML] Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview

C Chen, JM Lü, Q Yao - Medical science monitor: international …, 2016 - ncbi.nlm.nih.gov
Uric acid is the final oxidation product of purine metabolism in humans. Xanthine
oxidoreductase (XOR) catalyzes oxidative hydroxylation of hypoxanthine to xanthine to uric …

A Hydrogel Microneedle Assay Combined with Nucleic Acid Probes for On‐Site Detection of Small Molecules and Proteins

F Keyvani, H Zheng, MR Kaysir… - Angewandte …, 2023 - Wiley Online Library
Point‐of‐care testing (POCT) of clinical biomarkers is critical to health monitoring and timely
treatment, yet biosensing assays capable of detecting biomarkers without the need for costly …

Hyperuricemia and cardiovascular disease

S Zhang, Y Wang, J Cheng, N Huangfu… - Current …, 2019 - ingentaconnect.com
Purine metabolism in the circulatory system yields uric acid as its final oxidation product,
which is believed to be linked to the development of gout and kidney stones. Hyperuricemia …

[HTML][HTML] Management of hyperuricemia in patients with chronic kidney disease: a focus on renal protection

JT Kielstein, R Pontremoli, M Burnier - Current Hypertension Reports, 2020 - Springer
Abstract Purpose of Review In chronic kidney disease (CKD), plasma uric acid levels are
increased because of the decrease in glomerular filtration rate. However, in addition to CKD …